Biotechnology Value Fund L P - Net Worth and Insider Trading
Biotechnology Value Fund L P Net Worth
The estimated net worth of Biotechnology Value Fund L P is at least $1.0 Billion dollars as of 2024-11-05. Biotechnology Value Fund L P is the of Kymera Therapeutics Inc and owns about 5,054,898 shares of Kymera Therapeutics Inc (KYMR) stock worth over $238 Million. Biotechnology Value Fund L P is the of Xenon Pharmaceuticals Inc and owns about 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) stock worth over $127 Million. Biotechnology Value Fund L P is also the of Cullinan Therapeutics Inc and owns about 7,415,823 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $118 Million. Besides these, Biotechnology Value Fund L P also holds XOMA Royalty Corp (XOMA) , Olema Pharmaceuticals inc (OLMA) , ChemoCentryx Inc (CCXI) , MoonLake Immunotherapeutics (MLTX) , Repare Therapeutics Inc (RPTX) , Alpine Immune Sciences Inc (ALPN) , Cytokinetics Inc (CYTK) , Eledon Pharmaceuticals Inc (ELDN) , CTI BioPharma Corp (CTIC) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , Third Harmonic Bio Inc (THRD) , Concert Pharmaceuticals Inc (CNCE) , GlycoMimetics Inc (GLYC) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) . Details can be seen in Biotechnology Value Fund L P's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Biotechnology Value Fund L P has not made any transactions after 2024-10-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Biotechnology Value Fund L P
Biotechnology Value Fund L P Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Biotechnology Value Fund L P owns 52 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Royalty Corp (XOMA) among others .
Click here to see the complete history of Biotechnology Value Fund L P’s form 4 insider trades.
Insider Ownership Summary of Biotechnology Value Fund L P
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
FPRX | Five Prime Therapeutics Inc | 2020-11-11 | 10 percent owner |
ELDN | Eledon Pharmaceuticals Inc | 2023-05-05 | other: See Explanation of Responses |
XOMA | XOMA Royalty Corp | 2023-01-06 | other: See Explanation of Responses |
2021-10-08 | other: See Explanation of Responses | ||
2023-11-03 | other: See Explanation of Responses | ||
2020-08-18 | other: See Explanation of Responses | ||
2021-02-02 | other: See Explanation of Responses | ||
2020-05-21 | other: See Explanation of Responses | ||
2022-08-09 | other: See Explanation of Responses | ||
2020-12-09 | other: See Explanation of Responses | ||
2019-09-06 | other: See Explanation of Responses | ||
2020-11-04 | other: See Explanation of Responses | ||
2019-06-10 | other: See Explanation of Responses | ||
2021-02-11 | other: See Explanation of Responses | ||
2018-12-04 | other: See Explanation of Responses | ||
2017-11-28 | other: See Explanation of Responses | ||
2018-05-30 | other: See Explanation of Responses | ||
2017-08-15 | other: See Explanation of Responses | ||
2017-11-17 | other: See Explanation of Responses | ||
2017-07-14 | 10 percent owner & other: Direct Beneficial Owner | ||
2017-06-20 | other: See Explanation of Responses | ||
2016-06-23 | 10 percent owner | ||
2015-11-04 | other: See Explanation of Responses | ||
2009-07-09 | other: Direct Beneficial Owner | ||
2008-11-06 | 10 percent owner & other: Direct Beneficial Owners | ||
2014-03-21 | other: See Explanation of Responses | ||
2011-10-05 | other: See Explanation of Responses | ||
2013-05-01 | other: See Explanation of Responses | ||
2008-02-20 | 10 percent owner & other: Direct Beneficial Owner | ||
2009-12-22 | other: Direct Beneficial Owner | ||
2009-12-18 | 10 percent owner | ||
2009-10-21 | other: Direct Beneficial Owner | ||
2008-10-23 | 10 percent owner & other: Indirect Beneficial Owners | ||
2009-05-15 | 10 percent owner & other: Group Member | ||
2009-02-03 | 10 percent owner & other: Indirect Beneficial Owners | ||
2006-06-06 | 10 percent owner & other: Indirect Beneficial Owner | ||
2006-01-12 | other: Direct Beneficial Owner | ||
2004-07-07 | other: Direct Beneficial Owner | ||
2003-10-27 | other: Direct Beneficial Owner | ||
2017-02-10 | other: See Explanation of Responses | ||
2020-12-18 | other: See Explanation of Responses | ||
2022-01-25 | other: See Explanation of Responses | ||
2022-11-08 | other: See Explanation of Responses | ||
2023-09-12 | 10 percent owner | ||
2022-06-01 | other: See Explanation of Responses | ||
2023-11-16 | other: See Explanation of Responses | ||
2024-10-04 | director & 10 percent owner | ||
2022-06-16 | other: See Explanation of Responses | ||
2022-07-11 | 10 percent owner | ||
2024-10-29 | other: See Explanation of Responses | ||
2023-02-03 | other: See Explanation of Responses | ||
2023-12-18 | other: See Explanation of Responses |
Biotechnology Value Fund L P Latest Holdings Summary
Biotechnology Value Fund L P currently owns a total of 26 stocks. Among these stocks, Biotechnology Value Fund L P owns 5,054,898 shares of Kymera Therapeutics Inc (KYMR) as of November 3, 2023, with a value of $238 Million and a weighting of 23.6%. Biotechnology Value Fund L P owns 3,049,626 shares of Xenon Pharmaceuticals Inc (XENE) as of August 15, 2017, with a value of $127 Million and a weighting of 12.62%. Biotechnology Value Fund L P also owns 7,415,823 shares of Cullinan Therapeutics Inc (CGEM) as of June 1, 2022, with a value of $118 Million and a weighting of 11.7%. The other 23 stocks XOMA Royalty Corp (XOMA) , Olema Pharmaceuticals inc (OLMA) , ChemoCentryx Inc (CCXI) , MoonLake Immunotherapeutics (MLTX) , Repare Therapeutics Inc (RPTX) , Alpine Immune Sciences Inc (ALPN) , Cytokinetics Inc (CYTK) , Eledon Pharmaceuticals Inc (ELDN) , CTI BioPharma Corp (CTIC) , Arqule Inc (ARQL) , Merus NV (MRUS) , IDEAYA Biosciences Inc (IDYA) , Rain Oncology Inc (RAIN) , Five Prime Therapeutics Inc (FPRX) , Immune Design Corp (IMDZ) , Third Harmonic Bio Inc (THRD) , Concert Pharmaceuticals Inc (CNCE) , GlycoMimetics Inc (GLYC) , Pieris Pharmaceuticals Inc (PIRS) , Capstone Holding Corp (CAPS) , Calithera Biosciences Inc (CALA) , Infinity Pharmaceuticals Inc (INFIQ) , POINT Biopharma Global Inc (PNT) have a combined weighting of 52.08% among all his current holdings.
Latest Holdings of Biotechnology Value Fund L P
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
KYMR | Kymera Therapeutics Inc | 2023-11-03 | 5,054,898 | 47.07 | 237,934,049 |
XENE | Xenon Pharmaceuticals Inc | 2017-08-15 | 3,049,626 | 41.70 | 127,169,404 |
CGEM | Cullinan Therapeutics Inc | 2022-06-01 | 7,415,823 | 15.90 | 117,911,586 |
XOMA | XOMA Royalty Corp | 2023-01-06 | 3,645,542 | 30.86 | 112,501,426 |
OLMA | Olema Pharmaceuticals inc | 2023-09-12 | 8,897,173 | 11.86 | 105,520,472 |
CCXI | ChemoCentryx Inc | 2015-11-04 | 1,251,914 | 51.99 | 65,087,009 |
MLTX | MoonLake Immunotherapeutics | 2024-10-04 | 1,287,768 | 46.40 | 59,752,435 |
RPTX | Repare Therapeutics Inc | 2023-11-16 | 10,166,943 | 3.59 | 36,499,325 |
ALPN | Alpine Immune Sciences Inc | 2017-06-20 | 507,040 | 64.97 | 32,942,389 |
CYTK | Cytokinetics Inc | 2020-12-09 | 463,244 | 51.48 | 23,847,801 |
ELDN | Eledon Pharmaceuticals Inc | 2023-05-05 | 4,288,005 | 4.83 | 20,711,064 |
CTIC | CTI BioPharma Corp | 2022-08-09 | 2,271,791 | 9.09 | 20,650,580 |
ARQL | Arqule Inc | 2018-05-30 | 771,305 | 20.00 | 15,426,100 |
MRUS | Merus NV | 2021-10-08 | 232,747 | 51.23 | 11,923,629 |
IDYA | IDEAYA Biosciences Inc | 2021-02-02 | 233,150 | 30.00 | 6,994,500 |
RAIN | Rain Oncology Inc | 2022-11-08 | 3,288,186 | 1.21 | 3,978,705 |
FPRX | Five Prime Therapeutics Inc | 2020-11-11 | 81,263 | 38.00 | 3,087,994 |
IMDZ | Immune Design Corp | 2018-12-04 | 370,391 | 5.85 | 2,166,787 |
THRD | Third Harmonic Bio Inc | 2024-10-29 | 176,692 | 12.10 | 2,137,973 |
CNCE | Concert Pharmaceuticals Inc | 2019-06-10 | 169,589 | 8.37 | 1,419,460 |
GLYC | GlycoMimetics Inc | 2020-11-04 | 630,453 | 0.41 | 258,486 |
PIRS | Pieris Pharmaceuticals Inc | 2019-09-06 | 3,927 | 16.98 | 66,690 |
CAPS | Capstone Holding Corp | 2017-07-14 | 2,268 | 3.20 | 7,258 |
CALA | Calithera Biosciences Inc | 2020-05-21 | 24,022 | 0.01 | 168 |
INFIQ | Infinity Pharmaceuticals Inc | 2021-02-11 | 534,847 | 0.00 | 0 |
PNT | POINT Biopharma Global Inc | 2023-12-18 | 0 | 12.50 | 0 |
Holding Weightings of Biotechnology Value Fund L P
Biotechnology Value Fund L P Form 4 Trading Tracker
According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 8 transactions in Kymera Therapeutics Inc (KYMR) over the past 5 years, including 8 buys and 0 sells. The most-recent trade in Kymera Therapeutics Inc is the acquisition of 414,105 shares on November 3, 2023, which cost Biotechnology Value Fund L P around $5 Million.
According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 0 transactions in Xenon Pharmaceuticals Inc (XENE) over the past 5 years. The most-recent trade in Xenon Pharmaceuticals Inc is the acquisition of 60,202 shares on August 15, 2017, which cost Biotechnology Value Fund L P around $157,127.
According to the SEC Form 4 filings, Biotechnology Value Fund L P has made a total of 3 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cullinan Therapeutics Inc is the acquisition of 751,396 shares on June 1, 2022, which cost Biotechnology Value Fund L P around $8 Million.
More details on Biotechnology Value Fund L P's insider transactions can be found in the Insider Trading History of Biotechnology Value Fund L P table.Insider Trading History of Biotechnology Value Fund L P
- 1
Biotechnology Value Fund L P Trading Performance
GuruFocus tracks the stock performance after each of Biotechnology Value Fund L P's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Biotechnology Value Fund L P is 30.17%. GuruFocus also compares Biotechnology Value Fund L P's trading performance to market benchmark return within the same time period. The performance of stocks bought by Biotechnology Value Fund L P within 3 months outperforms 55 times out of 106 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Biotechnology Value Fund L P's insider trading performs compared to the benchmark.
Performance of Biotechnology Value Fund L P
Biotechnology Value Fund L P Ownership Network
Ownership Network List of Biotechnology Value Fund L P
Ownership Network Relation of Biotechnology Value Fund L P
Biotechnology Value Fund L P Owned Company Details
What does Five Prime Therapeutics Inc do?
Who are the key executives at Five Prime Therapeutics Inc?
Biotechnology Value Fund L P is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Bvf Partners L P/il , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .
Five Prime Therapeutics Inc (FPRX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Five Prime Therapeutics Inc Insider Transactions
Biotechnology Value Fund L P Mailing Address
Above is the net worth, insider trading, and ownership report for Biotechnology Value Fund L P. You might contact Biotechnology Value Fund L P via mailing address: 44 Montgomery Street, 40th Fl, San Francisco Ca 94104.